Regulators accused of bias against cannabis based medicinesBMJ 2001; 322 doi: http://dx.doi.org/10.1136/bmj.322.7288.691 (Published 24 March 2001) Cite this as: BMJ 2001;322:691
- Annabel Ferriman
A select committee of Britain's House of Lords this week accused the Medicines Control Agency of not dealing with cannabis based medicines in the same impartial manner as it dealt with other medicines.
In its report it said that the agency's insistence that new toxicology data were needed on one of the 60 cannabinoids present in raw cannabis would delay the approval of new cannabis based medicines, which patients with severe conditions, such as multiple sclerosis, needed.
The select committee on science and technology also deplored the “postcode prosecuting” of people who used …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial